Literature DB >> 19726986

Can convective therapies improve dialysis outcomes?

Francesco Locatelli1, Celestina Manzoni, Andrea Cavalli, Salvatore Di Filippo.   

Abstract

PURPOSE OF REVIEW: Convective treatments are characterized by enhanced removal of middle and large molecular weight solutes, important in the genesis of many complications of hemodialysis, compared with conventional low-flux hemodialysis. The availability of these techniques represented an intriguing innovation and a possible means to improve the still poor prognosis of hemodialysis patients. In this study we will critically review the most important published studies evaluating the impact of convective treatments on dialysis outcomes. RECENT
FINDINGS: The Hemodialysis (HEMO) study showed that greater urea removal nonsignificantly reduces the relative risk of mortality and that also high-flux hemodialysis was associated with a nonsignificant reduction, although a secondary analysis pointed to an advantage for high-flux membranes in subgroups of patients. More recently, the Membrane Permeability Outcome (MPO) study found that survival could be improved by use of high-flux membranes compared with low-flux dialysis in high-risk patients as identified by serum albumin < or =4 g/dl as well as in people with diabetes. In an observational study, hemodiafiltration with large reinfusion volume has been associated with a lower relative risk of mortality, compared with low-flux hemodialysis.
SUMMARY: The biologic plausibility of advantages of convective treatments and the results of the MPO and Dialysis Outcomes and Practice Patterns (DOPPS) studies are supporting rationales for the use of convective treatments to improve survival and delay long-term complications of hemodialysis patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19726986     DOI: 10.1097/MNH.0b013e3283318e8b

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  4 in total

Review 1.  Hemodiafiltration: the addition of convective flow to hemodialysis.

Authors:  Michel Fischbach; Helen Fothergill; Arianne Zaloszyc; Laure Seuge
Journal:  Pediatr Nephrol       Date:  2011-02-06       Impact factor: 3.714

Review 2.  Genomic damage in endstage renal disease-contribution of uremic toxins.

Authors:  Nicole Schupp; August Heidland; Helga Stopper
Journal:  Toxins (Basel)       Date:  2010-10-11       Impact factor: 4.546

3.  Erythrocyte glutathione transferase: a new biomarker for hemodialysis adequacy, overcoming the Kt/V(urea) dogma?

Authors:  A Noce; M Ferrannini; R Fabrini; A Bocedi; M Dessì; F Galli; G Federici; R Palumbo; N Di Daniele; G Ricci
Journal:  Cell Death Dis       Date:  2012-08-23       Impact factor: 8.469

4.  Comparison of toxin removal outcomes in online hemodiafiltration and intra-dialytic exercise in high-flux hemodialysis: a prospective randomized open-label clinical study protocol.

Authors:  Vaibhav Maheshwari; Lakshminarayanan Samavedham; Gade Pandu Rangaiah; Yijun Loy; Lieng Hsi Ling; Sunil Sethi; Titus Lau Wai Leong
Journal:  BMC Nephrol       Date:  2012-11-23       Impact factor: 2.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.